MARKET

LRMR

LRMR

Larimar Therapeutics Inc
NASDAQ
3.380
-0.100
-2.87%
After Hours: 3.500 +0.12 +3.55% 19:37 07/11 EDT
OPEN
3.400
PREV CLOSE
3.480
HIGH
3.480
LOW
3.340
VOLUME
687.18K
TURNOVER
--
52 WEEK HIGH
11.20
52 WEEK LOW
1.610
MARKET CAP
216.41M
P/E (TTM)
-2.2665
1D
5D
1M
3M
1Y
5Y
1D
Promising Potential of Larimar Therapeutics’ Nomlabofusp in Friedreich’s Ataxia: A Buy Rating Justified
TipRanks · 2d ago
Positive Outlook for Larimar Therapeutics: Promising Data on Nomlabofusp and Anticipated Catalysts Drive Buy Rating
TipRanks · 4d ago
Larimar Therapeutics’ nomlabofusp shows therapeutic potential in FA
TipRanks · 5d ago
Larimar Highlights Data for Rare Disease Drug Nomlabofusp in FDA Briefing
Benzinga · 5d ago
Weekly Report: what happened at LRMR last week (0630-0704)?
Weekly Report · 6d ago
Weekly Report: what happened at LRMR last week (0623-0627)?
Weekly Report · 06/30 11:59
Promising Regulatory Progress and Market Potential for Larimar Therapeutics
TipRanks · 06/26 09:06
Larimar Therapeutics (LRMR) Gets a Buy from Guggenheim
TipRanks · 06/26 06:46
More
About LRMR
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Webull offers Larimar Therapeutics Inc stock information, including NASDAQ: LRMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LRMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LRMR stock methods without spending real money on the virtual paper trading platform.